CTLA4 and prostate neoplasm: This is further supported by a recent study by Ariyan et al. [37] in which mice bearing a transplantable prostate tumor (TRAMPC2) treated with gemcitabine plus α-CTLA-4 experienced longer median survival (<125 days) than mice treated with gemcitabine monotherapy (72 days, p < 0.05).